Lumos Diagnostics Holdings Ltd (LDX) - Total Assets
Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) holds total assets worth AU$20.81 Million AUD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lumos Diagnostics Holdings Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Lumos Diagnostics Holdings Ltd's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lumos Diagnostics Holdings Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Lumos Diagnostics Holdings Ltd's total assets of AU$20.81 Million consist of 31.0% current assets and 69.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$1.96 Million | 9.4% |
| Accounts Receivable | AU$1.04 Million | 5.0% |
| Inventory | AU$521.00K | 2.5% |
| Property, Plant & Equipment | AU$6.17 Million | 29.6% |
| Intangible Assets | AU$8.18 Million | 39.3% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Lumos Diagnostics Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lumos Diagnostics Holdings Ltd's current assets represent 31.0% of total assets in 2024, an increase from 9.2% in 2017.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, up from 2.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 37.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 39.3% of total assets.
Lumos Diagnostics Holdings Ltd Competitors by Total Assets
Key competitors of Lumos Diagnostics Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
PolarCool AB (publ)
F:98H0
|
Germany | €10.79 Million |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
Lumos Diagnostics Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.74 | 0.76 | 3.02 |
| Quick Ratio | 0.68 | 0.69 | 2.91 |
| Cash Ratio | 0.22 | 0.51 | 0.00 |
| Working Capital | AU$-2.25 Million | AU$-3.07 Million | AU$13.74 Million |
Lumos Diagnostics Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Lumos Diagnostics Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.84 |
| Latest Market Cap to Assets Ratio | 5.25 |
| Asset Growth Rate (YoY) | -22.5% |
| Total Assets | AU$20.81 Million |
| Market Capitalization | $109.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lumos Diagnostics Holdings Ltd's assets at a significant premium (5.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Lumos Diagnostics Holdings Ltd's assets decreased by 22.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual total assets of Lumos Diagnostics Holdings Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$20.81 Million | -22.45% |
| 2023-12-31 | AU$26.84 Million | +5.58% |
| 2022-12-31 | AU$25.42 Million | -31.19% |
| 2021-12-31 | AU$36.94 Million | -62.30% |
| 2020-12-31 | AU$97.99 Million | +223.62% |
| 2019-12-31 | AU$30.28 Million | +19.20% |
| 2018-12-31 | AU$25.40 Million | +185.64% |
| 2017-12-31 | AU$8.89 Million | -- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more